{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T20:28:58Z","timestamp":1785443338510,"version":"3.56.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ctrv.2024.102867","type":"journal-article","created":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T16:28:53Z","timestamp":1734798533000},"page":"102867","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Practical clinical management of ocular adverse events related to Antibody-Drug Conjugates in gynaecological malignancies"],"prefix":"10.1016","volume":"134","author":[{"given":"Bochra","family":"Bouguerra Zina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9rique","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Fauquier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaud","family":"Sabatier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Kfoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.ctrv.2024.102867_b0005","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102867_b0010","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S1470-2045(17)30313-3","article-title":"Trastuzumab emtansine versus treatment of physician\u2019s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial","volume":"18","author":"Krop","year":"2017","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102867_b0015","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.ctrv.2024.102867_b0020","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.ctrv.2024.102867_b0025","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102867_b0030","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab Vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102867_b0035","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Coleman","year":"2021","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.ctrv.2024.102867_b0040","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.22.01900","article-title":"Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study","volume":"41","author":"Matulonis","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102867_b0045","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","article-title":"Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I","volume":"32","author":"Moore","year":"2021","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.ctrv.2024.102867_b0050","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102867_b0055","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40959-020-00081-9","article-title":"Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer","volume":"6","author":"Sardesai","year":"2020","journal-title":"Cardio-Oncol"},{"key":"10.1016\/j.ctrv.2024.102867_b0060","unstructured":"ImmunoGen Inc. (2024). Elahere: Summary of Product Characteristics (SmPC). Retrieved from https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/elahere-epar-product-information_en.pdf."},{"issue":"3","key":"10.1016\/j.ctrv.2024.102867_b0065","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ygyno.2007.11.020","article-title":"Folate receptor alpha as a tumor target in epithelial ovarian cancer","volume":"108","author":"Kalli","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2024.102867_b0070","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1158\/1535-7163.MCT-14-1095","article-title":"IMGN853, a folate receptor-\u03b1 (FR\u03b1)\u2013targeting antibody\u2013drug conjugate, exhibits potent targeted antitumor activity against FR\u03b1-expressing tumors","volume":"14","author":"Ab","year":"2015","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102867_b0075","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1470-2045(18)30859-3","article-title":"Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1\u20132 trial","volume":"20","author":"De Bono","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102867_b0080","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa2313811","article-title":"Tisotumab vedotin as second- or third-line therapy for recurrent cervical cancer","volume":"391","author":"Vergote","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102867_b0085","doi-asserted-by":"crossref","first-page":"213","DOI":"10.5858\/arpa.2012-0617-OA","article-title":"A Retrospective population-based comparison of HER2 immunohistochemistry and fluorescence in situ hybridization in breast carcinomas: impact of 2007 American society of clinical oncology\/ college of American pathologists criteria","volume":"138","author":"Schalper","year":"2014","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102867_b0090","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102867_b0095","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1158\/1535-7163.MCT-23-0287","article-title":"Raludotatug Deruxtecan, a CDH6-Targeting Antibody\u2013Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, Is Efficacious in Human Ovarian and Kidney Cancer Models","volume":"23","author":"Suzuki","year":"2024","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2024.102867_b0100","doi-asserted-by":"crossref","first-page":"S510","DOI":"10.1016\/j.annonc.2023.09.1924","article-title":"745MO Raludotatug deruxtecan (R-DXd; DS-6000) monotherapy in patients with previously treated ovarian cancer (OVC): Subgroup analysis of a first-in-human phase I study","volume":"34","author":"Moore","year":"2023","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102867_b0105","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1159\/000522206","article-title":"Trophoblast cell surface antigen 2 expression in human tumors: a tissue microarray study on 18,563 tumors","volume":"89","author":"Dum","year":"2022","journal-title":"Pathobiology"},{"key":"10.1016\/j.ctrv.2024.102867_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.08.776","article-title":"714MO Datopotamab deruxtecan (Dato-DXd) in patients with endometrial (EC) or ovarian cancer (OC): results from the phase II TROPION-PanTumor03 study","volume":"35","author":"Oaknin","year":"2024","journal-title":"Ann Oncol"},{"issue":"29","key":"10.1016\/j.ctrv.2024.102867_b0115","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1200\/JCO.23.02767","article-title":"Efficacy and safety of sacituzumab govitecan in patients with advanced solid tumors (TROPiCS-03): analysis in patients with advanced endometrial cancer","volume":"42","author":"Santin","year":"2024","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102867_b0120","article-title":"Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132","volume":"23","author":"Cheng","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2024.102867_b0125","article-title":"715MO Safety and efficacy of sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced endometrial carcinoma (EC) and ovarian cancer (OC) from a phase II study","volume":"35","author":"Wang","year":"2024","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2024.102867_b0130","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40265-021-01507-z","article-title":"Ocular toxicity of targeted anticancer agents","volume":"81","author":"Fortes","year":"2021","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102867_b0135","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1097\/ICO.0000000000002934","article-title":"Refractive shifts and changes in corneal curvature associated with antibody\u2013drug conjugates","volume":"41","author":"Canestraro","year":"2022","journal-title":"Cornea"},{"key":"10.1016\/j.ctrv.2024.102867_b0140","article-title":"Structural changes of corneal epithelium in belantamab-associated superficial keratopathy using anterior segment optical coherence tomography","volume":"23","author":"Matsumiya","year":"2021","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102867_b0145","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10637-017-0520-6","article-title":"Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads","volume":"36","author":"Masters","year":"2018","journal-title":"Invest New Drugs"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102867_b0150","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/19420862.2016.1156829","article-title":"Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates","volume":"8","author":"Donaghy","year":"2016","journal-title":"mAbs."},{"issue":"10","key":"10.1016\/j.ctrv.2024.102867_b0155","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/jop.2015.0064","article-title":"Ocular adverse events associated with antibody\u2013drug conjugates in human clinical trials","volume":"31","author":"Eaton","year":"2015","journal-title":"J Ocul Pharmacol Ther"},{"issue":"16_suppl","key":"10.1016\/j.ctrv.2024.102867_b0160","doi-asserted-by":"crossref","first-page":"9039","DOI":"10.1200\/JCO.2022.40.16_suppl.9039","article-title":"Safety and efficacy of tusamitamab ravtansine (SAR408701) in long-term treated patients with nonsquamous non\u2013small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)","volume":"40","author":"Ricordel","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102867_b0165","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1158\/1078-0432.CCR-18-2474","article-title":"Evaluation of prophylactic corticosteroid eye drop use in the management of corneal abnormalities induced by the antibody\u2013drug conjugate mirvetuximab soravtansine","volume":"25","author":"Matulonis","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102867_b0170","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41571-023-00783-w","article-title":"Optimizing the safety of antibody\u2013drug conjugates for patients with solid tumours","volume":"20","author":"Tarantino","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102867_b0175","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1470-2045(24)00140-2","article-title":"Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study","volume":"25","author":"Li","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2024.102867_b0180","unstructured":"Seagen Inc. and Genmab A\/S. (2024). TIVDAK (tisotumab vedotin-tftv) prescribing information. U.S. Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761208s007lbl.pdf."},{"key":"10.1016\/j.ctrv.2024.102867_b0185","doi-asserted-by":"crossref","unstructured":"R. Arn, APRN-CNP C, J. Halla, MSN, FNP-C K, Gill, RN (Hons) S. Tisotumab Vedotin Safety and Tolerability in Clinical Practice: Managing Adverse Events. J Adv Pract Oncol. 2023;14(2):139\u201352.","DOI":"10.6004\/jadpro.2023.14.2.4"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102867_b0190","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11882-019-0844-8","article-title":"Emerging therapeutics for ocular surface disease","volume":"19","author":"Bielory","year":"2019","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.ctrv.2024.102867_b0195","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2147\/OPTO.S259398","article-title":"Over-the-counter ocular decongestants in the united states \u2013 mechanisms of action and clinical utility for management of ocular redness","volume":"12","author":"Hosten","year":"2020","journal-title":"Clin Optom"},{"key":"10.1016\/j.ctrv.2024.102867_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102720","article-title":"Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan","volume":"125","author":"Heist","year":"2024","journal-title":"Cancer Treat Rev"},{"issue":"16","key":"10.1016\/j.ctrv.2024.102867_b0205","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1002\/cncr.30736","article-title":"Phase 1 dose\u2010escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor \u03b1\u2010targeting antibody\u2010drug conjugate, in patients with solid tumors","volume":"123","author":"Moore","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2024.102867_b0210","article-title":"Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine","volume":"47","author":"Hendershot","year":"2023","journal-title":"Gynecol Oncol Rep"},{"issue":"11","key":"10.1016\/j.ctrv.2024.102867_b0215","article-title":"Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma","volume":"11","author":"Wahab","year":"2021","journal-title":"Front Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.ctrv.2024.102867_b0220","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood-2020-142069","article-title":"Acute myeloid leukemia\/myelodysplastic syndrome (AML\/MDS) associated with PARP inhibitors: a real-world analysis","volume":"136","author":"Gajra","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102867_b0225","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","article-title":"2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours","volume":"47","author":"Aapro","year":"2011","journal-title":"Eur J Cancer"},{"issue":"18 Suppl","key":"10.1016\/j.ctrv.2024.102867_b0230","article-title":"Overview of the prevention and management of CINV","volume":"24","author":"Natale","year":"2018","journal-title":"Am J Manag Care"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102867_b0235","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10549-021-06280-x","article-title":"Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies","volume":"188","author":"Dempsey","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"10.1016\/j.ctrv.2024.102867_b0240","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/psp4.13007","article-title":"Exposure-safety and exposure-efficacy analyses for tisotumab vedotin for patients with locally advanced or metastatic solid tumors","volume":"12","author":"Passey","year":"2023","journal-title":"CPT Pharmacomet Syst Pharmacol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737224001968?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737224001968?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T09:27:12Z","timestamp":1744190832000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737224001968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":48,"alternative-id":["S0305737224001968"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102867","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Practical clinical management of ocular adverse events related to Antibody-Drug Conjugates in gynaecological malignancies","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102867","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102867"}}